HKSE - Delayed Quote HKD

PuraPharm Corporation Limited (1498.HK)

0.750 0.000 (0.00%)
At close: April 26 at 2:07 PM GMT+8

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Yu Ling Chan Founder, Chairman & CEO 3.66M -- 1961
Ms. Yee Wai Man M.B.A., B.Sc., MBA, BBS Executive Director 1.25M -- 1966
Mr. Kwun Kiu Cheung Financial Controller -- -- 1986
Ms. Hang Woon Ma Head of Brand & Corporate Marketing -- -- --
Ms. Pui Hung Group Human Resources Director -- -- --
Mr. Kar Fai Kwong Head of Supply Chain -- -- --
Ms. Charmayne Chan Company Secretary -- -- 1983
Ms. Jian Zhou Nanning Production Director -- -- --

PuraPharm Corporation Limited

Wireless Centre, Phase One
Unit 201-207, 2/F Hong Kong Science Park
Tai Po
Hong Kong
852 2840 1840 https://www.purapharm.com
Sector: 
Healthcare
Full Time Employees: 
662

Description

PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it provides modernized Chinese medicine services, and Chinese medical diagnostic services. The company sells its products to hospitals, healthcare institutions, and medicine practitioners, as well as operates an online store. The company was founded in 1998 and is headquartered in Tai Po, Hong Kong.

Corporate Governance

PuraPharm Corporation Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • May 31, 2017
    Ex-Dividend Date

Upcoming Events

Mar 28, 2024
PuraPharm Corporation Limited Earnings Call